News
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...
TipRanks on MSN18h
FibroGen Gains Approval for Subsidiary Sale to AstraZeneca
FibroGen ( ($FGEN) ) just unveiled an announcement. On August 18, 2025, FibroGen announced that it received regulatory approval from the China ...
Stocktwits on MSN20h
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...
Second Quarter 2025 Results Key Financial Results Net loss: US$13.7m (loss narrowed by ...
6d
FibroGen, Inc.: FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now esti ...
Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback